Communiqués SELLAS Life Sciences Group, Inc.

Actions

SLS

US81642T2096

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 11/08/2026			Varia. 5j.	Varia. 1 janv.
11,05 ^USD	+0,09%		-6,44%	+193,10%

29/06	Social Buzz : Les valeurs de Wallstreetbets progressent en avant-bourse lundi ; SELLAS Life Sciences et Strategy attendus en hausse	MT
12/05	SELLAS Life Sciences Group : réduction de la perte nette au premier trimestre	MT

Communiqués

22:06	SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update	AQ
14/05	SELLAS Life Sciences to Participate in Upcoming Investor Conferences	AQ
12/05	SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update	AQ
19/03	SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update	AQ
17/03	SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference	AQ
12/03	SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009	AQ
14/01	SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe	AQ
30/12	SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia	AQ
29/12	SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)	AQ
08/12	SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025	AQ
12/11	SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update	AQ
03/11	SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting	AQ
27/10/25	SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds	AQ
22/10/25	SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum	AQ
13/10/25	SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025	AQ
30/09/25	SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update	AQ
11/09/25	SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds	AQ
12/08/25	SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update	AQ
07/08/25	SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification	AQ
01/08/25	SELLAS Life Sciences : Corporate Presentation - August 2025	PU
15/07/25	SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study	AQ
07/07/25	SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board	AQ
24/06/25	SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes	AQ
05/06/25	SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts	AQ
02/06/25	SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting	AQ